Navigation Links
China Sky One Medical Provides Sales Forecast for 13 New Products

HARBIN, China, May 12 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today provided an update on the commercialization plan for the 13 new products. Based on additional market research and customer feedback, the Company estimates aggregate incremental 2010 sales of approximately $4 million from these products.

In March and April, the Company successfully launched the following three products as planned: Oxymetazoline Hydrochloride Nasal Drops for acute and chronic rhinitis, sinusitis and allergic rhinitis; Moschus Liniment for relief of pain from scathe, wound, rheumatism and arthrosis; Ftibamzone Liniment to treating herpes and fungal skin infection.

    The remaining ten new products will be launched during the rest of 2010.

    Product Name                Description                    Expected Launch
    Tobramycin Eye     To treat acute infection on eyelids         May 2010
    Calcium Folinate   An auxiliary therapy for sprue (a           May 2010
     Injection         disease of the small intestine),
                       malnutrition, pregnancy- or infancy-
                       related megaloblastic anemia, and
                       colonic and rectal cancer
    Sodium             To treat allergic conjunctivitis            May 2010
     Eye Drops
    Aciclovir Gel      To treat the skin infection due to         June 2010
                       varicella-zoster virus and the herpes
                       simplex virus
    Antiasthma cream   To treat cough, asthma and chronic         June 2010
    Naphazoline        For the sterilization and rheum            June 2010
     Hydrochloride     prevention and for the treatment
     Chlorpheniramine  of rheumatic diseases
     Maleate and
     Bromide Spray
    Skincare Cream     To treat skin diseases such as acne,       July 2010
                       bottle nose, chromophytosis
                       and vitiligo
    Nasal Drop         To treat the snuffle                     August 2010
    Propylgallate      To treat cerebro-vascular infarction,    August 2010
     for Injection     angina, hypertention and coronary
                       heart diseases
    Dithranol          to treat different types of           September 2010
     ointment          psoriasis, such as plaque psoriasis,
                       guttate psoriasis and hypertrophy

"We look forward to the commercial launch of the remaining ten new products in 2010. China Sky One remains committed to the research and development of new products to create more growth opportunities in the long-term," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include the production timeline and its effect on the Company's operational results. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the ability to launch new products, market acceptance of new product launches, achievability of management's estimates of product sales, the effect of changing economic conditions in The People's Republic of China, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For further information, please contact:

    Company Contact:

    China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-0451-8703-2617

    Investor Relations Contact:

    CCG Investor Relations
     Ms. Lei Huang, Account Manager
     Tel:   +1-646-833-3417

     Ms. Mabel Zhang, Vice President
     Tel:   +1-310-954-1353

SOURCE China Sky One Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... and the Organization of Black Aerospace Professionals (OPBAP) has been formalized with the ... other AMA team leaders met with OPBAP leaders Capt. Karl Minter and Capt. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... featured on AngelList early in their initial angel funding process. Now, they are ... individuals looking to make early stage investments in the microbiome space. In ...
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is ... it is bound to proteins, copper is also toxic to cells. With a ... Polytechnic Institute (WPI) will conduct a systematic study of copper in the bacteria ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... market report published by Transparency Market Research "Home Security Solutions ... and Forecast 2015 - 2022", the global home security solutions ... bn by 2022. The market is estimated to expand ... from 2015 to 2022. Rising security needs among customers ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
(Date:10/27/2015)... 2015 Munich, Germany ... technology (ASGM) automatically maps data from mobile eye tracking ... , so that they can be quantitatively analyzed with ... Munich, Germany , October 28-29, 2015. SMI,s Automated ... mobile eye tracking videos created with SMI,s Eye ...
Breaking Biology News(10 mins):